Sanofi's Pipeline Weakness Likely to Hamper Growth -- Market Talk

Dow Jones2025-12-31

0848 GMT - Sanofi's increased investment in research and development hasn't helped it avoid significant setbacks over the past two years, Baader Europe analyst Abhishek Raval writes. Recent ones include the underwhelming performance of the immunology treatment amlitelimab, which raised concerns over the French pharma group's growth after its Dupixent drug loses patent exclusivity in the early 2030s, Raval says. This and other trial disappointments lead Baader to lower its growth estimate for coming years to 1.5% from 2%. A flurry of merger activity might be how Sanofi is compensating for pipeline weakness and could cause concern over whether it can cut its overdependence on external innovation, Raval adds. Shares fall 0.2% to 82.81 euros and have fallen 12% year to date. (william.gray@wsj.com)

(END) Dow Jones Newswires

December 31, 2025 03:49 ET (08:49 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2595722257?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-31 16:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595722257","market":"sh","top_or_hot":-1,"title":"Sanofi's Pipeline Weakness Likely to Hamper Growth -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0848 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>'s increased investment in research and development hasn't helped it avoid significant setbacks over the past two years, Baader Europe analyst Abhishek Raval writes. Recent ones include the underwhelming performance of the immunology treatment amlitelimab, which raised concerns over the French pharma group's growth after its Dupixent drug loses patent exclusivity in the early 2030s, Raval says. This and other trial disappointments lead Baader to lower its growth estimate for coming years to 1.5% from 2%. A flurry of merger activity might be how <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> is compensating for pipeline weakness and could cause concern over whether it can cut its overdependence on external innovation, Raval adds. Shares fall 0.2% to 82.81 euros and have fallen 12% year to date. (william.gray@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 31, 2025 03:49 ET (08:49 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's Pipeline Weakness Likely to Hamper Growth -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's Pipeline Weakness Likely to Hamper Growth -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-31 16:49</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0848 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>'s increased investment in research and development hasn't helped it avoid significant setbacks over the past two years, Baader Europe analyst Abhishek Raval writes. Recent ones include the underwhelming performance of the immunology treatment amlitelimab, which raised concerns over the French pharma group's growth after its Dupixent drug loses patent exclusivity in the early 2030s, Raval says. This and other trial disappointments lead Baader to lower its growth estimate for coming years to 1.5% from 2%. A flurry of merger activity might be how <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> is compensating for pipeline weakness and could cause concern over whether it can cut its overdependence on external innovation, Raval adds. Shares fall 0.2% to 82.81 euros and have fallen 12% year to date. (william.gray@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 31, 2025 03:49 ET (08:49 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2595722257","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595722257","pubTimestamp":1767170940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0848 GMT - Sanofi's increased investment in research and development hasn't helped it avoid significant setbacks over the past two years, Baader Europe analyst Abhishek Raval writes. Recent ones include the underwhelming performance of the immunology treatment amlitelimab, which raised concerns over the French pharma group's growth after its Dupixent drug loses patent exclusivity in the early 2030s, Raval says. This and other trial disappointments lead Baader to lower its growth estimate for coming years to 1.5% from 2%. A flurry of merger activity might be how Sanofi is compensating for pipeline weakness and could cause concern over whether it can cut its overdependence on external innovation, Raval adds. Shares fall 0.2% to 82.81 euros and have fallen 12% year to date. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","SNY":"赛诺菲安万特","BK4585":"ETF&股票定投概念","BK4007":"制药","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","SNYNF":"Sanofi"},"translate_title":"市场传言，赛诺菲的管道弱点可能会阻碍增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":0.9,"SNYNF":1.5},"content_text":"0848 GMT - Sanofi's increased investment in research and development hasn't helped it avoid significant setbacks over the past two years, Baader Europe analyst Abhishek Raval writes. Recent ones include the underwhelming performance of the immunology treatment amlitelimab, which raised concerns over the French pharma group's growth after its Dupixent drug loses patent exclusivity in the early 2030s, Raval says. This and other trial disappointments lead Baader to lower its growth estimate for coming years to 1.5% from 2%. A flurry of merger activity might be how Sanofi is compensating for pipeline weakness and could cause concern over whether it can cut its overdependence on external innovation, Raval adds. Shares fall 0.2% to 82.81 euros and have fallen 12% year to date. (william.gray@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 31, 2025 03:49 ET (08:49 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595722257","isCrawlerRequest":true}